| [1] |
Ahlawat S, Fayad LM, Khan MS, et al. Current whole⁃body MRI applications in the neurofibromatoses: NF1, NF2, and schwanno⁃matosis[J]. Neurology, 2016, 87(7 Suppl 1): S31⁃39. DOI: 10. 1212/WNL.0000000000002929.
|
| [2] |
Ahlawat S, Fayad LM, Khan MS, et al. Current whole⁃body MRI applications in the neurofibromatoses: NF1, NF2, and schwanno⁃matosis[J]. Neurology, 2016, 87(7 Suppl 1): S31⁃39. DOI: 10. 1212/WNL.0000000000002929.
|
| [3] |
Messiaen L, Callens T, Mortier G, et al. Exhaustive mutation analysis of the NF1gene allows identification of 95 of mutations and reveals a highfrequency of unusual splicing defects. Hum Mutat 2000, 15(6): 541⁃555. DOI: 10.1002/1098⁃1004(200006)15:6<541::AID⁃HUMU6>3.0.CO;2⁃N.
|
| [4] |
Brems H, Chmara M, Sahbatou M, et al. Germline loss⁃of⁃function mutations in SPRED1 cause a neurofibromatosis 1⁃like phenotype[J]. NatGenet, 2007, 39(9): 1120⁃1126. DOI: 10.1038/ng2113.
|
| [5] |
Messiaen L, Yao S, Brems H, et al. Clinical and mutational spectrum of neurofibromatosis type 1⁃like syndrome[J]. JAMA, 2009, 302(19): 2111⁃2118. DOI: 10.1001/jama.2009.1663.
|
| [6] |
Brems H, Beert E, de Ravel T, et al. Mechanisms in the pathogenesis of malignant tumours in neurofibromatosis type 1[J]. Lancet Oncol, 2009, 10(5): 508⁃515. DOI: http://dx.doi.org/10.1016/S1470⁃2045(09)70033⁃6.
|
| [7] |
Beert E, Brems H, Renard M, et al. Biallelic inactivation of NF1 in a sporadic plexiformneurofibroma[J]. Genes Chromosomes Cancer, 2012, 51(9): 852⁃857. DOI: 10.1002/gcc.21969.
|
| [8] |
Jouhilahti EM, Peltonen S, Heape AM, et al. The pathoetiology of neurofibromatosis 1[J]. Am J Pathol, 2011, 178(5): 1932⁃1939. DOI: 10.1016/j.ajpath.2010.12.056.
|